Moderna began COVID-19 vaccine trials on children aged between six months and 12 years, according to a statement on Tuesday. The first participants were administered doses in the Phase 2/3 study, called the KidCOVE study, the US pharmaceutical and biotechnology said. "We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess ...